Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Regeneron

This page shows the latest Regeneron news and features for those working in and with pharma, biotech and healthcare.

Regeneron scores positive data in phase 3 cholesterol trial

Regeneron scores positive data in phase 3 cholesterol trial

Targets severe inherited disorder. Regeneron’s pipeline candidate evinacumab reduced LDL cholesterol by 49% in patients with an inherited disorder which causes high cholesterol levels. . ... Regeneron and partner Sanofi have another approved

Latest news

More from news
Approximately 58 fully matching, plus 134 partially matching documents found.

Latest Intelligence

  • Innovation and digital health comms recognised at Communiqué Awards Innovation and digital health comms recognised at Communiqué Awards

    Innovation in Healthcare Communications. One high profile winning campaign was Havas Lynx Group’s ‘See Below’ on behalf of Sanofi Genzyme and Regeneron.

  • Immuno-oncology in 2019: the rapid evolution continues Immuno-oncology in 2019: the rapid evolution continues

    In addition to the PD-1 inhibitors Keytruda and Opdivo, there are four PD-L1 inhibitors: Roche’s Tecentriq, AstraZeneca’s Imfinzi, Pfizer and Merck’s Bavencio and Sanofi and

  • Regeneron and Bluebird sign $100m cell therapies deal Regeneron and Bluebird sign $100m cell therapies deal

    If Regeneron chooses not to opt-in, it will receive milestone payments and royalties from Bluebird on any potential resulting products. ... The deal involves Regeneron making a $100 million investment in Bluebird stock, at a premium of 59% over its

  • The good, the bad and the ugly The good, the bad and the ugly

    Ophthalmology. Ophthalmology is dominated by a small number of the same therapies marketed by different companies in different regions; Regeneron, Bayer and Santen all market Eylea, whereas Novartis and Roche market ... Regeneron remains the leading

  • Deal Watch October 2016 Deal Watch October 2016

    330. Ocular Therapeutics (US). Regeneron (US). Licence collaboration. Hydrogel sustained release aflibercept (Eylea) for wet macular degeneration.

More from intelligence
Approximately 1 fully matching, plus 15 partially matching documents found.

Latest appointments

  • Tiziana Life Sciences appoints clinical sciences VP Tiziana Life Sciences appoints clinical sciences VP

    Prior to this, Dr Evans held a number of scientific leadership positions while at Amgen, Johnson &Johnson and Regeneron.

  • Regeneron taps Pfizer for CFO Regeneron taps Pfizer for CFO

    Robert Landry succeeds Murray Goldberg. Former Pfizer senior VP Robert Landry has joined Regeneron as senior VP, finance, and will later take over as chief financial officer. ... We are extremely fortunate that Murray will stay at Regeneron through 2014

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Quick links

Infographics

Multimedia